Clinical Implications of Phosphorylated STAT3 Expression in De Novo Diffuse Large B-cell Lymphoma

Purpose: Activated signal transducer and activator of transcription 3 (STAT3) regulates tumor growth, invasion, cell proliferation, angiogenesis, immune response, and survival. Data regarding expression of phosphorylated (activated) STAT3 in diffuse large B-cell lymphoma (DLBCL) and the impact of phosphorylated STAT3 (pSTAT3) on prognosis are limited. Experimental Design: We evaluated expression of pSTAT3 in de novo DLBCL using immunohistochemistry, gene expression profiling (GEP), and gene set enrichment analysis (GSEA). Results were analyzed in correlation with cell-of-origin (COO), critical lymphoma biomarkers, and genetic translocations. Results: pSTAT3 expression was observed in 16% of DLBCL and was associated with advanced stage, multiple extranodal sites of involvement, activated B-cell–like (ABC) subtype, MYC expression, and MYC/BCL2 expression. Expression of pSTAT3 predicted inferior overall survival (OS) and progression-free survival (PFS) in patients with de novo DLBCL. When DLBCL cases were stratified according to COO or MYC expression, pSTAT3 expression did not predict inferior outcome, respectively. Multivariate analysis showed that the prognostic predictability of pSTAT3 expression was due to its association with the ABC subtype, MYC expression, and adverse clinical features. GEP demonstrated upregulation of genes, which can potentiate function of STAT3. GSEA showed the JAK–STAT pathway to be enriched in pSTAT3+ DLBCL. Conclusions: The results of this study provide a rationale for the ongoing successful clinical trials targeting the JAK–STAT pathway in DLBCL. Clin Cancer Res; 20(19); 5113–23. ©2014 AACR.

[1]  O. Coqueret,et al.  Opposite regulation of Myc and p21waf1 transcription by STAT3 proteins. , 2014, The Journal of Biological Chemistry.

[2]  P. Qiu,et al.  Gefitinib resistance resulted from STAT3-mediated Akt activation in lung cancer cells , 2013, Oncotarget.

[3]  L. Staudt,et al.  Activation of the STAT3 signaling pathway is associated with poor survival in diffuse large B-cell lymphoma treated with R-CHOP. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  W. Choi,et al.  MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. , 2013, Blood.

[5]  Y. Oki,et al.  Phase I Study of Panobinostat plus Everolimus in Patients with Relapsed or Refractory Lymphoma , 2013, Clinical Cancer Research.

[6]  J. Briones,et al.  MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy , 2013, Haematologica.

[7]  W. Choi,et al.  MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. , 2013, Blood.

[8]  H. Maehr,et al.  Targeting CD44-STAT3 Signaling by Gemini Vitamin D Analog Leads to Inhibition of Invasion in Basal-Like Breast Cancer , 2013, PloS one.

[9]  Hua Yu,et al.  Prognostic Significance of B-Cells and pSTAT3 in Patients with Ovarian Cancer , 2013, PloS one.

[10]  T. Witzig,et al.  Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP. , 2012, Blood.

[11]  W. Choi,et al.  Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. , 2012, Blood.

[12]  K. Dybkær,et al.  Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study , 2012, Leukemia.

[13]  J. Cultrera,et al.  Diffuse large B-cell lymphoma: current strategies and future directions. , 2012, Cancer control : journal of the Moffitt Cancer Center.

[14]  M. Gupta,et al.  Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy , 2012, Leukemia.

[15]  S. Mustjoki,et al.  Somatic STAT3 mutations in large granular lymphocytic leukemia. , 2012, The New England journal of medicine.

[16]  Li Lin,et al.  STAT3 is necessary for proliferation and survival in colon cancer-initiating cells. , 2011, Cancer research.

[17]  Gang Wu,et al.  Expression of CDK5/p35 in resected patients with non-small cell lung cancer: relation to prognosis , 2011, Medical oncology.

[18]  Jun Zhu,et al.  High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma , 2011, Journal of hematology & oncology.

[19]  Hua Yu,et al.  STAT3 inhibition is a therapeutic strategy for ABC-like diffuse large B-cell lymphoma. , 2011, Cancer research.

[20]  M. Karin,et al.  Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. , 2010, Cytokine & growth factor reviews.

[21]  Hua Yu,et al.  Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. , 2009, Cancer cell.

[22]  S. Pileri,et al.  Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas , 2009, Modern Pathology.

[23]  A. Mansoor,et al.  pY-STAT3 and p53 expression predict outcome for poor prognosis diffuse large B-cell lymphoma treated with high dose chemotherapy and autologous stem cell transplantation , 2009, Leukemia & lymphoma.

[24]  L. Staudt,et al.  Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma. , 2008, Blood.

[25]  W. Gerald,et al.  Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. , 2007, The Journal of clinical investigation.

[26]  G. Cattoretti,et al.  Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. , 2007, Blood.

[27]  G. Stark,et al.  Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. , 2007, Genes & development.

[28]  W. Gerald,et al.  Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer , 2007, Breast Cancer Research.

[29]  A. Fersht,et al.  Structural basis for understanding oncogenic p53 mutations and designing rescue drugs , 2006, Proceedings of the National Academy of Sciences.

[30]  K. Aldape,et al.  Activation of stat3 in human melanoma promotes brain metastasis. , 2006, Cancer research.

[31]  E. Verdin,et al.  NF‐κB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation , 2006, The EMBO journal.

[32]  R. Gascoyne,et al.  Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Jianyuan Luo,et al.  Activation of Stat3 Sequence-specific DNA Binding and Transcription by p300/CREB-binding Protein-mediated Acetylation* , 2005, Journal of Biological Chemistry.

[34]  B. Barton,et al.  Novel single-stranded oligonucleotides that inhibit signal transducer and activator of transcription 3 induce apoptosis in vitro and in vivo in prostate cancer cell lines. , 2004, Molecular cancer therapeutics.

[35]  Hua Yu,et al.  The STATs of cancer — new molecular targets come of age , 2004, Nature Reviews Cancer.

[36]  Nicola Gebbia,et al.  STAT proteins: From normal control of cellular events to tumorigenesis , 2003, Journal of cellular physiology.

[37]  Rafael A Irizarry,et al.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.

[38]  Rolf Rossaint,et al.  Activation of STAT3 by IL-6 and IL-10 in Primary Human Macrophages Is Differentially Modulated by Suppressor of Cytokine Signaling 3 1 , 2003, The Journal of Immunology.

[39]  S. Bhattacharya,et al.  Regulation of Stat3 nuclear export. , 2003, The Journal of clinical investigation.

[40]  Terence P. Speed,et al.  A comparison of normalization methods for high density oligonucleotide array data based on variance and bias , 2003, Bioinform..

[41]  T. Yeatman,et al.  Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[42]  J Diebold,et al.  Prognostic significance of survivin expression in diffuse large B-cell lymphomas. , 2000, Blood.

[43]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[44]  J. Darnell,et al.  Stat3 as an Oncogene , 1999, Cell.

[45]  T. Hirano,et al.  Stat3 Is Required for the Gp130-mediated Full Activation of the C-myc Gene , 1999 .

[46]  T. Hirano,et al.  Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of STAT3 in anti-apoptosis. , 1996, Immunity.

[47]  J. Darnell,et al.  Maximal activation of transcription by statl and stat3 requires both tyrosine and serine phosphorylation , 1995, Cell.

[48]  W. Choi,et al.  Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP , 2014, Modern Pathology.

[49]  K. Dybkær,et al.  Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study , 2014, Leukemia.

[50]  Hua Yu,et al.  Tumour immunology: Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment , 2007, Nature Reviews Immunology.